Market Size of Global Viral Clearance Services Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 15.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Viral Clearance Services Market Analysis
The viral Clearance Services Market is Poised to grow at a CAGR of 15% over the forecast period. The major factors attributing to the growth of the market are the rising need for viral clearance and the increasing demand for specialty drugs
COVID-19 has a significant impact on the market studied. During COVID-19, the isolation of patients was the priority across the globe. A study published in the Journal of Infection and Chemotherapy in June 2021 stated that a classification of the isolation times based on age could be taken into consideration while processing the viral clearance since the length of the viral clearance periods from COVID-19 patients can vary with age. Due to biases including underlying medical disorders, it may be challenging to establish a uniform viral clearance duration for elderly patients. With the increased incidence of COVID-19, the demand for viral clearance was raised which contributed to the growth of the market.
Viral clearance studies are a necessary component of any regulatory submission for clinical trials or approval of all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove inactivated viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house.
Biological and biotechnological products are at risk from impurities, bacteria and fungi, and viruses. With such products, the potential for transmission of viral diseases is a real risk. Viral contamination can affect raw materials, cell culture processes, bioreactor contamination, and downstream processing. It is for these reasons that pharmaceutical organizations practice viral safety and incorporate virus clearance into the manufacturing process.
